vTv Therapeutics Inc. (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 1,358,698 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $1.84 per share, with a total value of $2,500,004.32.
vTv Therapeutics Inc. (NASDAQ:VTVT) shares ticked up 2.27% to finally closed at $1.35 in last active session.
VTVT’s distance from 20 day simple moving average is -10.98% and distance from 50-Day simple moving average is -9.55%.
Analyst’s mean target price for VTVT is $6.50 while analysts mean recommendation is 2.00. Stock value has moved between $0.68 – 6.14 in last one year. Stock has got OUTPERFORM rating from 1 of Thomson Reuters analysts, 0 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for VTVT is $6.50 while analysts mean recommendation is 2.00.
vTv Therapeutics Inc. (NASDAQ:VTVT) yearly performance is -14.01%. Annual EPS Growth of past 5 years is 13.90%. The current share price indicates that stock is -77.83% away from its one year high and is moving 97.54% ahead of its 52-week low.